SecBot SecBot
SECBOTREPLAY Home › Report › LRMR

LRMR · Larimar Therapeutics reported Q4 and full-year 2025 financial results,…

Larimar Therapeutics · PRESS-RELEASE filed Mar 19, 2026 at 07:00 ET

At the news

MIXEDIMPACT 7/10

PRESS-RELEASE filed Mar 19, 2026 at 07:00 ET

Larimar Therapeutics reported Q4 and full-year 2025 financial results, highlighted by Breakthrough Therapy Designation from the FDA for nomlabofusp in Friedreich’s ataxia, a $107.6M public offering, and $244.5M in pro forma cash extending runway into Q2 2027. However, net losses widened significantly year-over-year due to increased R&D spending, particularly in manufacturing scale-up.

  • FDA granted Breakthrough Therapy Designation for nomlabofusp in Friedreich’s ataxia, supporting accelerated approval pathway.
  • BLA submission for nomlabofusp remains on track for June 2026, with U.S. launch targeted in first-half 2027 if approved.
  • Topline data from open-label study expected in Q2 2026 to support BLA; global Phase 3 study to initiate screening in Q2 2026.
  • Completed $115M public offering in February 2026, generating $107.6M in net proceeds.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access